Mission Viejo, California-based Innovasive, Inc. has officially changed its name to Amplify Surgical, Inc. and has undertaken a corporate rebranding process.
Innovasive Changes Name to Amplify Surgical
1 min read Premium comments
Secondary#interbodyfusion#amplifysurgical#innovasive
“The Amplify Surgical name better emphasizes our commitment to delivering new, cutting-edge, surgical solutions that reestablish the standard of care for our surgeon customers and their patients,” explained company CEO Andy Choi. “In addition, the new name and brand better represents the Company’s inventive culture and product pipeline.”
According to Amplify Surgical, “In October 2018, the Company received U.S. Food and Drug Administration (FDA) clearance for its first product, dualX – the Dual Expanding Interbody Fusion System. DualX is comprised of a family of titanium expandable interbody devices designed to be used in transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF) and lateral lumbar interbody fusion (LLIF) spinal procedures. The product portfolio contains varying footprints, heights and degrees of lordosis with post-expansion bone grafting to provide a customized, anatomical fit for a clinically-successful fusion environment.”
Andy Choi told OTW, “We changed our name to better emphasize the company’s commitment to delivering new, cutting-edge, surgical solutions that reestablish the standard of care for our surgeon customers and their patients. Amplify Surgical better represents our corporate culture and product pipeline.”
A company representative added that the company is quickly moving forward with the rebranding effort and have just launched the new website amplifysurgical.com.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.